Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma

Human Pathology

Volumn 40, Issue 9, 2009, Pages 1304-1311

  Yonemitsu, Yutaka ^a   Imazeki, Fumio ^a   Chiba, Tetsuhiro ^a   Fukai, Kenichi ^a   Nagai, Yuichiro ^a   Miyagi, Satoru ^a   Arai, Makoto ^a   Aoki, Ryutaro ^a   Miyazaki, Masaru ^a   Nakatani, Yukio ^a   Iwama, Atsushi ^a   Yokosuka, Osamu ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

BMI1; EZH2; Hepatocellular carcinoma; MTS assay; Short hairpin RNA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; BMI1 PROTEIN; POLYCOMB GROUP PROTEIN; PROTEIN EZH2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SURGERY; CELL GROWTH; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DNA-BINDING PROTEINS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; TRANSCRIPTION FACTORS;

EID: 68349150322     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.01.017     Document Type: Article

References (24)

1. Valk-Lingbeek M.E., Bruggeman S.W.M., and van Lohuizen M. Stem cells and cancer: the polycomb connection. Cell 118 (2004) 409-418
2. Sparmann A., and van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6 (2006) 846-856
3. Iwama A., Oguro H., Negishi M., et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product, Bmi-1. Immunity 21 (2004) 843-851
4. Gil J., and Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7 (2006) 667-677
5. Oguro H., Iwama A., Morita Y., Kamijo T., van Lohuizen M., and Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 203 (2006) 2247-2253
6. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 112 (2001) 950-958
7. Croonquist P.A., and Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24 (2005) 6269-6280
8. van Lohuizen M., Verbeek S., Scheijen B., Wientjens E., van der Gulden H., and Berns A. Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging. Cell 65 (1991) 737-752
9. Smith K.S., Chanda S.K., Lingbeek M., et al. Bmi-1 regulation of INK4A-ARF is a downstream requirement for transformation of hematopoietic progenitors by E2a-Pbx1. Mol Cell 12 (2003) 393-400
10. Mohty M., Yong A.S., Szydlo R.M., Apperley J.F., and Melo J.V. The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia. Blood 110 (2007) 380-383
11. Chowdhury M., Mihara K., Yasunaga S., Ohtaki M., Takihara Y., and Kimura A. Expression of Polycomb-group (PcG) protein BMI-1 predicts prognosis in patients with acute myeloid leukemia. Leukemia. 21 (2007) 1116-1122
12. van Kemenade F.J., Raaphorst F.M., Blokzijl T., et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 (2001) 3896-3901
13. Varambally S., Dhanasekaran S.M., Zhou M., et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
14. Kleer C.G., Cao Q., Varambally S., et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100 (2003) 11606-11611
15. Kim J.H., Yoon S.Y., Jeong S.H., et al. Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast 13 (2004) 383-388
16. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 2nd English ed. (2003), Kanehara & Co., Ltd., Tokyo
17. Wang B.E., Ma W.M., Sulaiman A., et al. Demographic, clinical, and virological characteristics of hepatocellular carcinoma in Asia: survey of 414 patients from four countries. J Med Virol 67 (2002) 394-400
18. Colombo M., and Donato M.F. Prevention of hepatocellular carcinoma. Semin Liver Dis 25 (2005) 155-161
19. Bruix J., Boix L., Sala M., and Llovet J.M. Focus on hepatocellular carcinoma. Cancer Cell 5 (2004) 215-219
20. Roberts L.R., and Gores G.J. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25 (2005) 212-225
21. Sudo T., Utsunomiya T., Mimori K., et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 92 (2005) 1754-1758
22. Chen Y., Lin M.C., Yao H., et al. Lentivirus-mediated RNA interference targeting enhancer of zeste homolog 2 inhibits hepatocellular carcinoma growth through down-regulation of stathmin. Hepatology 46 (2007) 200-208
23. Sasaki M., Ikeda H., Itatsu K., et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 00 00 (2008) 1-10
24. INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 215 (2008) 175-183